BioWorld

Jan. 21, 2019

View Archived Issues

Money raised by biotech: 2019 vs. 2018

Biopharma money raised: Jan. 1 - 17, 2019

Week in review

Week in Washington

Word on the street

Conference data: December 2018

Regulatory submissions, approvals and other actions: December 2018

Handing over the dealmaking torch, 2018 logs monster biopharma deals, paves the way for top M&As

Biopharma licensing deals signed in 2018 climbed to 1,364 and have a projected value of $119.54 billion, a four-year high for an industry still riding the immuno-oncology wave. Read More

The week's biggest gainers and losers

BioWorld stock report for public biotechnology companies

Today's news in brief

BioWorld

BioWorld briefs for July 31, 2026.

AIDS 2026: New targets for metabolic dysfunction despite ART

BioWorld

Although antiretroviral therapy (ART) can suppress HIV to undetectable levels, a growing body of evidence suggests that the virus leaves a lasting biological...

Jingxin discloses new muscarinic and sigma receptor agonists

BioWorld Science

Shanghai Jingxin Biopharmaceutical Co. Ltd. and Zhejiang Jingxin Pharmaceutical Co. Ltd. have synthesized new muscarinic acetylcholine receptor and sigma receptor...

Silhouette illustration of DNA gene editing

Death in Chinese gene-editing trial exposes ethical fault lines

BioWorld

The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...

Fauci’s silence may put him in contempt of Congress

BioWorld

After repeatedly invoking the Fifth Amendment to every question asked during the July 29 hearing of the U.S. Senate Homeland Security Committee, Anthony Fauci,...